ライフサイエンスコーパス: disappoint

1 ic transcription during development were not disappointed.

2 vasculitis and myasthenia gravis were rather disappointing.

3 om a generation ago, is generally still very disappointing.

4 how brain processes cause consciousness are disappointing.

5 ght to drive tumor growth, results have been disappointing.

6 factor control in clinical practice has been disappointing.

7 for acute myeloid leukemia (AML) has proved disappointing.

8 cines in phase IIa/b clinical trials remains disappointing.

9 rods and found that this approach is rather disappointing.

10 ing genes for multifactorial stroke has been disappointing.

11 whose cause is unclear and treatment remains disappointing.

12 compounds in human clinical trials has been disappointing.

13 to acetylcholinesterase inhibitors is often disappointing.

14 presenting at an advanced stage is therefore disappointing.

15 mpts to solve this problem have been largely disappointing.

16 alone in this patient group has proven to be disappointing.

17 ere developed, but clinical trials have been disappointing.

18 and the replication among studies is rather disappointing.

19 nfarction (AMI) for patient benefit has been disappointing.

20 unmodified antisense RNAs has generally been disappointing.

21 d in patients with myeloma, and results were disappointing.

22 the outcome of cell transplantation remains disappointing.

23 r peripheral nerve repair in humans is often disappointing.

24 y-dwelling adults, which, to date, have been disappointing.

25 on anticoagulation duration has largely been disappointing.

26 However, clinical studies have so far been disappointing.

27 hat adherence to health education advice was disappointing.

28 nism, and VEGF delivery to patients has been disappointing.

29 thic pain in small fibre neuropathy is often disappointing.

30 s with known proangiogenic factors have been disappointing.

31 sis to provide improved resolution have been disappointing.

32 ion to the diagnostic armamentarium has been disappointing.

33 us clinical trials with this agent have been disappointing.

34 t of fulminant colitis in children have been disappointing.

35 V squamous cell head and neck cancer remains disappointing.

36 urodegenerative diseases has been meager and disappointing.

37 overall survival with this approach has been disappointing.

38 in diseases where conventional DLI has been disappointing.

39 e clinical trials (oral administration) were disappointing.

40 tients with congenital corneal opacities are disappointing.

41 ment of bacterial vaginosis in pregnancy are disappointing.

42 pancreatography pancreatitis (ERCP) has been disappointing.

43 odies and nuclear medicine imaging have been disappointing.

44 ical effectiveness of immunotherapy has been disappointing.

45 ine therapy in the adjuvant setting has been disappointing.

46 human clinical trials have, in general, been disappointing.

47 ces and antiarrhythmic drug therapy has been disappointing.

48 ablation therapy for many patients has been disappointing.

49 onists in congestive heart failure have been disappointing.

50 IDs) in the treatment of AD have so far been disappointing.

51 t, is common and the 5-year survival rate is disappointing.

52 However, results have been disappointing.

53 nventional immunosuppressive agents has been disappointing.

54 ividual genetic abnormalities have also been disappointing.

55 patients with Parkinson's disease have been disappointing.

56 cells for therapeutic applications have been disappointing.

57 infarction, and hemorrhagic shock-have been disappointing.

58 but the results for larger tumors have been disappointing.

59 The results of these trials have been disappointing.

60 e results of islet transplantation have been disappointing.

61 complex traits has been difficult and often disappointing.

62 SWL) for lower calyceal stones are generally disappointing.

63 ent of autoimmune disease in humans has been disappointing.

64 g in-stent restenosis have been consistently disappointing.

65 improved clinical outcomes has been largely disappointing.

66 fusion to clinical practice has to date been disappointing.

67 ancers to immune therapies has thus far been disappointing.

68 trial results with HDACi have thus far been disappointing.

69 anoma, their use in ocular variants has been disappointing.

70 istors' power amplification ability has been disappointing.

71 ion of in vitro to in vivo findings is often disappointing.

72 -D monoclonal antibodies have been, at best, disappointing.

73 antioxidants have, however, been clinically disappointing.

74 ceutical, but subsequent investigations were disappointing.

75 Pharmacological treatments were disappointing.

76 rates to therapeutic clinical trials remain disappointing.

77 sults with anti-angiogenic therapy have been disappointing.

78 , gains from second-line therapies have been disappointing.

79 sults of clinical trials have generally been disappointing.

80 cardioversion in restoring sinus rhythm was disappointing.

81 romising results, trials in humans have been disappointing.

82 d some success, but outcomes post-ITx remain disappointing.

83 cancer antigen 125 as an antigen, have been disappointing.

84 inues, the clinical return has thus far been disappointing.

85 New treatments of refractory GERD have been disappointing.

86 Overall 5-year patient survival was a disappointing 35%.

87 s of sleep-disordered breathing have shown a disappointing ability to predict important consequences

88 ibition using sulfonylurea agents has proved disappointing, although agents acting on its pore appear

89 vitamin E supplements and cataract have been disappointing and are not yet available for selenium.

90 s to identify genetic variants have produced disappointing and contradictory results.

91 th oncogenic RAS signaling have been largely disappointing and have not resulted in meaningful clinic

92 py to inhaled corticosteroids, they are also disappointing and less effective than long-acting beta(2

93 Current treatments are disappointing and often have little beneficial effect.

94 immunosuppressive drugs has been relatively disappointing and there have been few efforts in definin

95 , clinical activity in solid tumors has been disappointing and toxicity has been a serious concern.

96 for persistent atrial fibrillation (AF) are disappointing and usually do not exceed 60%.

97 approaches to Alzheimer disease (AD) remain disappointing and, hence, there is an urgent need for ef

98 models are still widely used, but have been disappointing, and development of genetic models has giv

99 ept in the treatment of sarcoidosis has been disappointing, and may actually cause the disease.

100 ed epithelial ovarian carcinoma (EOC) remain disappointing, and the development of more effective pri

101 ted therapy for solid tumors has so far been disappointing, and the reasons for this poor response in

102 greater clinical impact than have the so far disappointing antisense endeavors.

103 tely, results from clinical trials have been disappointing as off-target effects and toxicities have

104 sis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encep

105 ials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate desi

106 of HCV treatment in this population has been disappointing because of low rates of treatment initiati

107 iences with EGFR kinase inhibitors have been disappointing, because resistance is common and tumors e

108 idual hormone/mediator have yielded somewhat disappointing body weight changes, often leading to the

109 candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns ab

110 an, interferon gamma, and relaxin) have been disappointing but new strategies against fibrosis based

111 icide candidates in efficacy trials has been disappointing, but next-generation concepts now in or ap

112 ediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmo

113 relish in scientific controversy will not be disappointed by the literature on the effects of sleep o

114 Considering the disappointing clinical activity of HSP90 inhibitors in o

115 targets and lead to improvement of the still disappointing clinical outcome of these patients.

116 fusion of red blood cells has been linked to disappointing clinical outcomes in the critically ill, b

117 eptor (EGFR)-targeted therapies have yielded disappointing clinical results in treatment of this canc

118 E) to prevent lung cancer have produced only disappointing clinical results to date.

119 vered, perhaps an explanation for the so-far disappointing clinical translation to the prevention and

120 ouraging experimental work has led so far to disappointing clinical trials and the identification of

121 ta in humans with one agent (infliximab) but disappointing controlled data from another (etanercept).

122 c strategies that will improve the currently disappointing cure rate (approximately 25-40%) of this g

123 myocardial infarction, have provided largely disappointing data.

124 hrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored an

125 geted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM t

126 autoimmune diseases have often been notably disappointing despite many claims for linkages.

127 It disappoints despite its relatively large size, conformat

128 w antibacterial agents has been particularly disappointing, despite a plethora of potential targets,

129 poptotic receptor agonists (PARAs) have been disappointing, despite compelling preclinical efficacy w

130 ng antioxidant supplements have been equally disappointing, despite the clear benefits of a healthy d

131 alysts, their enzymatic performance has been disappointing due to low reaction rates.

132 nisms for exercise hyperaemia are especially disappointing due to the essentially concurrent discover

133 ng program implementation, results have been disappointing, e.g., only 7% of candidates passing the p

134 ith two devices have been stopped because of disappointing early results.

135 n clinical trials, MEK inhibitors have shown disappointing efficacy in mutant NRAS patients, the reas

136 s for solid-organ transplantation have shown disappointing efficacy in the prevention of chronic allo

137 Disappointing efficacy of 11betaHSD1 inhibitors in phase

138 The disappointing efficacy of blood-stage malaria vaccines m

139 ain a better understanding of the clinically disappointing EGFR-targeted therapies for GBM, we invest

140 of the tests with glans swab specimens were disappointing except for those from patients with sympto

141 ecific antisense have resulted in an overall disappointing experience.

142 nagement strategies, highlighting the rather disappointing experiences with mechanical and systemic d

143 sharp contrast to the fit-to-cohort effect, disappointing findings to date, and limited reproducibil

144 ting vasculature may, in part, explain these disappointing findings.

145 rvival and overall survival, however, remain disappointing for children with metastatic RMS at diagno

146 However, blockade of EGFR is therapeutically disappointing for gliomas with PTEN deletion.

147 neic stem cell transplantation (SCT) but are disappointing for other diseases.

148 Nothing is more disappointing for patients than when a promising new tre

149 ise as a thermal material, results have been disappointing for practical thermal systems and applicat

150 initial clinical trials in humans have been disappointing, highlighting a need to optimize their imm

151 Despite a long disappointing history of human trials with neurotrophins

152 this burgeoning literature has thus far been disappointing, however, leaving open the question of whi

153 Effectiveness is then often disappointing in 'real life' conditions.

154 t in the context of atherosclerosis has been disappointing in clinical studies.

155 idual neurotrophic factors (NTF) have proved disappointing in clinical trials for neuronal repair and

156 gh increasing landscape complexity can prove disappointing in fields with low soil services or in int

157 Conversely, CBT has been relatively disappointing in follicular lymphoma and diffuse large B

158 xpensive and their immunogenicity has proven disappointing in human clinical trials, we have been exp

159 disease and even promising agents have been disappointing in large-scale clinical trials.

160 n animal models of ALS, but have been proven disappointing in part because effective targets have not

161 However, clinical trials have been disappointing in part to dose-limiting hypercalcemia.

162 onic laryngitis, cough, and asthma have been disappointing in showing benefit of acid suppressive the

163 other hand, offer safety but have often been disappointing in terms of efficiency of nuclear delivery

164 rength composite material, it exhibits quite disappointing in terms of modulus or strength.

165 chemical compounds-for other purposes-proved disappointing in tests against Ebola virus (EBOV) infect

166 me-wide association studies (GWAS) have been disappointing in the inability of investigators to use t

167 bal response to COVID-19 has been uneven and disappointing in the vast majority of countries.

168 mphoteric vectorization efforts proved to be disappointing in this series, aminoglycosidic and polyca

169 adder instillation of antibiotics has proved disappointing in treating UTI, likely due to the failure

170 Stimulation treatments have been disappointing in vegetative state but occasionally impro

171 ognosis, particularly in advanced stages, is disappointing largely due to the resistance to conventio

172 nts however, overall 5-year survival remains disappointing: less than 25% of patients live for 5 year

173 ) fusion F glycoprotein previously exhibited disappointing levels of RSV F immunogenicity and genetic

174 L tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typif

175 This past year has proved to be a relatively disappointing one for the development of agents that cou

176 inical trials into these therapies have been disappointing or conflicting.

177 mor necrosis factor-alpha activity have been disappointing, or of unproven benefit at best.

178 ssays, but with a precision of only 0.92%, a disappointing outcome that led to an examination of the

179 organic solar cells, although with a rather disappointing outcome to date in terms of efficiencies.

180 This disappointing outcome was traced to unfavorable pharmaco

181 rtant reasons are likely to account for this disappointing outcome, including failure to appreciate d

182 lection using drug resistance genes have had disappointing outcomes and/or require highly genotoxic m

183 Such disappointing outcomes clearly call for broadening the s

184 Disappointing outcomes in clinical trials aimed at augme

185 Disappointing outcomes of nano-sized formulations (nanof

186 which immune rejection contributes to these disappointing outcomes using an immunodeficient IL2 rece

187 istent atrial fibrillation (PersAF) have had disappointing outcomes, despite concerted clinical and r

188 systemic therapies, including taxanes, yield disappointing outcomes.

189 with the RXR ligand (rexinoid) have yielded disappointing outcomes.

190 er failure of those first-line therapies are disappointing overall, with many patients eventually req

191 d targeted therapy trials have thus far been disappointing owing to a lack of robust stratification m

192 ion methods of nanowire-like devices produce disappointing performance because of process-induced mat

193 Recent clinical setbacks and disappointing performance of preclinical compounds in an

194 wever, human trials with vitamin E have been disappointing, perhaps related to ineffective levels of

195 age of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans unde

196 outcomes of somatic cell transplants remain disappointing, presumably due to lack of appropriate sup

197 A major reason for disappointing progress of psychiatric diagnostics and no

198 th attendant inflated development costs) and disappointing progress.

199 ever, progression-free survival rates remain disappointing, ranging from 40% to 50%.

200 The disappointing recent failure of fluoroquinolone-containi

201 against specific tumors have so far produced disappointing results against ovarian cancer.

202 lipoprotein (LDL) in vitro and has displayed disappointing results against the onset and development

203 Despite this, programs have yielded disappointing results and can have unintended consequenc

204 therapy with rapamycin analogues has yielded disappointing results due in part to compensatory up-reg

205 ly responsive to chemotherapy, combined with disappointing results from a recent SCLC clinical trial

206 After disappointing results from all efficacy trials conducted

207 ossible cellular explanation contributing to disappointing results from anti-Abeta therapeutic trials

208 Disappointing results from most late-stage clinical tria

209 Disappointing results from recent trials of improved coo

210 diovascular disease paved the way to largely disappointing results from several large prevention tria

211 der in which conventional treatment leads to disappointing results in a proportion of patients.

212 DA-approved drug that has previously yielded disappointing results in clinical trials in patients wit

213 cause current pan-HDAC inhibitors have shown disappointing results in clinical trials of solid tumors

214 nation of why anti-EGFR therapies have shown disappointing results in clinical trials.

215 The disappointing results in humans should be taken as an op

216 with promising results in certain areas and disappointing results in others.

217 Some of these have yielded disappointing results in practice but are now of renewed

218 ion of the mismatch are also responsible for disappointing results in the application of perfusion-we

219 ation in immunologically fit individuals and disappointing results in the elderly and immunocompromis

220 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX); n

221 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX, sa

222 In contrast, oral agents have yielded disappointing results in the secondary prevention of acu

223 n infectious disease models but have yielded disappointing results in tumor models when tumor-associa

224 al limb ischemia all have contributed to the disappointing results of balloon angioplasty for complex

225 Despite the disappointing results of Explorer and Lunar trials, othe

226 This could explain the disappointing results of FGF-2 therapy in clinical trial

227 The lack of effective treatments, disappointing results of many HF randomized clinical tri

228 Angst over disappointing results of neuroprotection trials in Parki

229 trials, was then tempered by the subsequent disappointing results of randomized clinical trials.

230 e involving more diverse regimens, following disappointing results of retinoid monotherapy.

231 On the flip side, the disappointing results of rituximab in lupus nephritis pr

232 The disappointing results of the National Emphysema Treatmen

233 eart disease and may help explain the mostly disappointing results of this approach to date.

234 These disappointing results represent a policy failure within

235 These disappointing results stand in sharp contrast to estimat

236 ve been used in a small clinical trial, with disappointing results to date.

237 Disappointing results were announced for a number of lar

238 The disappointing results were attributed largely to poor ad

239 By contrast, disappointing results with antigen-based therapeutics hi

240 Unfortunately, there have been disappointing results with regard to improvement of tumo

241 Chemotherapy and radiation afford disappointing results, however, and novel therapies are

242 In light of these disappointing results, investigators have pursued altern

243 trials of glutamatergic modulators have had disappointing results, our growing understanding suggest

244 Despite disappointing results, two recent medication trials show

245 el mechanism-based treatments brought rather disappointing results, with low, if any, drug efficacy a

246 performed for hemangiosarcoma (HAS) despite disappointing results.

247 c therapy for ischemic heart disease has had disappointing results.

248 en evaluated in several clinical trials with disappointing results.

249 followed but were initially met with largely disappointing results.

250 dates, human trials have exclusively yielded disappointing results.

251 eradicate this viral reservoir have yielded disappointing results.

252 the myocardium using stem cells have yielded disappointing results.

253 mpts to improve adherence have often yielded disappointing results.

254 However, the clinical trials yielded disappointing results.

255 s of the inflammatory response, have yielded disappointing results.

256 y has been explored in myeloma patients with disappointing results.

257 ic strategies have so far yielded relatively disappointing results.

258 erapy for iliofemoral venous thrombosis with disappointing results.

259 w exceptions, empirical studies have yielded disappointing results.

260 ion against virion proteins but have yielded disappointing results.

261 ter bodies but several times with unexpected disappointing results.

262 test this possibility, however, have yielded disappointing results.

263 ase (PD) have produced variable, but overall disappointing, results.

264 ted at tumor necrosis factor alpha have been disappointing so far, although preliminary studies with

265 ut their effect on clinical outcome has been disappointing so far, except for saphenous vein bypass g

266 ical trials for acute pancreatitis have been disappointing, so strategies that target and alter the b

267 While this disappointing state of affairs may suggest that plasma p

268 ease-modifying approaches have been thus far disappointing, steady advances are being made in the sym

269 in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or func

270 Disappointing survival rates from out-of-hospital cardia

271 We are disappointed that the Cochrane Group remains unconvinced

272 HCT service use increased over time, it was disappointing that the proportions ever testing and ever

273 past 7 years, it has been surprising, almost disappointing, that germline MCU deficiency in mice with

274 These findings may explain the disappointing therapeutic effect of targeting IL-17A in

275 es using single targeted therapies have been disappointing, therefore providing the impetus for novel

276 What follows will disappoint those who await complaint and criticism, for

277 The results for other rTMS paradigms are disappointing thus far.

278 in efficacy and side effects that we were so disappointed to observe in recent clinical trials.

279 hase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have bee

280 hibitors targeting individual RTKs have been disappointing to date.

281 cardioprotective signaling has been largely disappointing to date.

282 usable system lasts for years." It is indeed disappointing to discover that your data resources are n

283 xplain variation in population risk had been disappointing until the advent of technologies that assa

284 asked to end the play, and the majority were disappointed when play was halted.

285 r prognostic accuracy of markers often prove disappointing when "discrimination" found between cancer

286 rials of antiangiogenic strategies have been disappointing when administered as single agents, such a

287 ise in some malignancies have generally been disappointing when applied to high-grade brain tumors su

288 ocyte transplantation for cirrhosis has been disappointing when compared with laboratory experience.

289 harmaceuticals targeting this class has been disappointing, where it has been a major problem to obta

290 Women were more likely than men to be disappointed with a 20% weight loss but were less likely

291 diminishing faith in medicine (patients were disappointed with aspects of their care-seeking experien

292 l violence was positively related to feeling disappointed with one's occupation, which was in turn po

293 clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of ~10%

294 les for diagnostic purposes have been rather disappointing with respect to their clinical validity, i

295 The enzyme has not disappointed, with subsequent demonstrations of remarkab

296 e resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suf

297 ndritic cell (DC)-based immunotherapy remain disappointing, with DCs often displaying a tenuous capac

298 of follow-up, longer-term results have been disappointing, with increased rates of device thrombosis

299 ed aimed at the PPTg, but outcomes have been disappointing, with little evidence that gait and postur

300 While numerous factors contributed to the disappointing yield, one factor was that essential genes